Head to head
Regeneron Pharmaceuticals vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: REGN · VRTX
REGN
Regeneron Pharmaceuticals
742.12+0.46%
1-year price shape — +28% over the period
Quant Rating C · 69/100
vs
VRTX
Vertex Pharmaceuticals
505.64+0.66%
1-year price shape — +23% over the period
Quant Rating C · 67/100
1-year performance, rebased to 100
Regeneron Pharmaceuticals edges it on the scoreable measures. Regeneron Pharmaceuticals has the highest Quant Rating (69); Regeneron Pharmaceuticals has done best over the past year (+28%); Regeneron Pharmaceuticals trades cheapest on trailing earnings.
| REGN | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 742.12 | 505.64 |
| Change today | +0.46% | +0.66% |
| 1-year return | +27.9% | +23.2% |
| Market cap | $76.40B | $128.16B |
| 52-week range | 538.24 – 859.34 | 402.58 – 560.25 |
| Valuation | ||
| P/E (TTM) | 18.36 | 29.45 |
| P/E percentile, own 5-yr range | 51st | 74th |
| P/B | 2.41 | 6.33 |
| Dividend yield | 0.49% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 41.48 | 15.32 |
| Net profit (TTM) | $4.27B | $3.88B |
| Revenue (TTM) | $15.53B | $12.59B |
| Revenue growth (YoY) | +16.7% | +12.5% |
| Gross margin | 84.9% | 86.0% |
| Operating margin | 26.9% | 37.9% |
| Net margin | 27.9% | 35.0% |
| Free cash flow (TTM) | $3.58B | $3.80B |
| Ownership & sentiment | ||
| Institutional ownership | 94.2% | 97.2% |
| Insider activity (12mo) | 27 buy / 23 sell | 25 buy / 25 sell |
| Short interest (% of float) | 2.5% | 1.9% |
| Analyst consensus | 63% buy / 37% hold (19) | 88% buy / 8% hold / 4% sell (24) |
| Analyst price target | $841 (+13%) | $580 (+15%) |
| StockVane view | ||
| StockVane Quant Rating | C (69) | C (67) |
| Company | ||
| Employees | 15,410 | 6,400 |
| Founded | 1988 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.